Elskan is an innovative product. The aim of this product is to offer a device for preventive cardiovascular diseases check and screening for population. Cardiovascular diseases, heart attacks or strokes, are a leading cause of death globally. 30% of deaths have been caused by cardiovascular diseases. as of today, there is no regular checkup to this disease. This is because the cost of device for such test is relatively expensive. Yet, it requires cardiologist considerable time for analyzing one patient's recorded results (of 24 hours ECG or heart beats). Elskan offer a special low cost device which will significantly reduce to monitoring cost time taken for cardiologists or specialists for recording analysis and reporting. This can make possible launching the preventive monitoring for population possible.
The product has been developed for over 7 years and recently obtained medical approval (interim) in Russia, subject to clinical trial, it can be launched in Russia for marketing and distribution. Russia is one of the countries with highers rate of this disease. The product is ready.
We are planning a clinical trials in UK and Australia, subject in coming months.
Growth potential is substantial. We expect to launch the monitoring in Eastern Europe and the UK in 2017. We expect to launch in UK market after regularly approval obtained in 2017. We have plan for launching the monitoring in other emerging markets.
This project would enable the public to be aware of the cardiovascular disease. As it has been proven that 90% of this disease can be prevented with factors of healthy eating, exercise, avoidance of tobacco smoking and limited alcohol intake.
We also plan to extend the monitoring of program to new-borns. It is estimated that 1 in 100 new borns are with congenital heart defects. If all new borns can be checked at very early (while they are still at hospitals or clinics), it would enable much early diagnosis of such problem and early action can be taken to take care of those with problems.